



Ami Organics Limited

CIN. : L24100GJ2007PLCO51093

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

August 12, 2024

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code : 543349

NSE Symbol : AMIORG

Subject: Investor Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on financial results for the first quarter ended as on June 30, 2024 and other business matters.

This Investor Presentation will also be made available on the website of the Company www.amiorganics.com.

Kindly take the same on record.

Yours faithfully,

For, AMI ORGANICS LIMITED

EKTA KUMARI
SRIVASTAVA

Digitally signed by EKTA
KUMARI SRIVASTAVA
Date: 2024.08.12
15:58:04 +05'30'

Ekta Kumari Srivastava
Company Secretary & Compliance Officer



Encl: Presentation



Info@amiorganics.com



www.amiorganics.com



+91 72279 77744 / 75730 15366

Investor Presentation

AUGUST 2024

BSE : 543349 | NSE : AMIORG | www.amiorganics.com



AMI ORGANICS LTD.

Table of Contents

01

Q1FY25 Results

02

Company Overview

03

Advanced Pharma
Intermediate

04

Specialty Chemicals

05

Working towards better
tomorrow

1. Q1FY25 Results

- Management Commentary
- Q1FY25 Earnings Highlights
- Q1FY25 Business Highlights
- Q1FY25 Financial Performance – Key Metrics
- Q1FY25 Financial Performance – P&L Statement
- Financial Performance over the years – Key Metrics
- Financial Performance over the years – Profit and Loss
- Financial Performance over the years – Balance Sheet
- Shareholder Information





Mr. Naresh Patel

Executive Chairman and Managing Director

Management Commentary

"I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of ₹176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase.

During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector.

Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year."

Revenue for Q1FY25
(Mn)

Rs. 1,767

↑ 14.9%

YoY

EBIDTA for Q1FY25
(Mn)

Rs. 295

↓ 13.2%

YoY

PAT for Q1FY25
(Mn)

Rs. 147

↓ 33.9%

YoY



Q1FY25 Earnings and Financial Highlights

- **Revenue from operations** for Q1FY24 grew by **14.9% YoY** to **Rs. 1,767 mn**
- The **gross margin** for the quarter was at **42.1%**.
- **EBITDA** for the quarter came at **Rs. 295 mn** down 13.2% YoY compared to Rs. 340 mn in Q1FY24.
- **EBITDA margin** for the quarter was at **16.7%** as compared to 22.1% in Q1FY24. EBITDA margins contraction was driven by gross margins coupled with higher employee expenses due to annual increments as well as new hiring for Ankleshwar plant.
- **PAT** for the quarter was **Rs. 147 mn**. The **PAT margin** for the quarter was **8.3%**. PAT margins were impacted due to higher finance cost as well as higher depreciation cost.

Q1FY25 Business Highlights

- Export at **63%**; domestic business at **37%**
- **Successfully concluded** Good Manufacturing Practices (**GMP**) **inspection** by Pharmaceutical and Medical Devices Agency, Japan ("**PMDA**") without any critical/major observation.
- Incorporated "**ENCHEM AMI ORGANICS PRIVATE LIMITED**", as a Wholly Owned Subsidiary Company of Ami Organics Electrolytes Private Limited (a Wholly owned subsidiary of Ami Organics Limited).
- **Funds Raised** – Successfully **raised Rs. 500cr. through QIP and Preferential allotment** to deleverage balance sheet and support capex.
- As of July 2024, **a total debt of Rs. 253cr** has been repaid and the company is now net debt zero company.



Q1FY25 Financial Performance – Key Metrics

Revenue from Operations


(Rs Mn)

YoY Growth

16.6%

9.8%

14.9%



EBITDA & EBITDA Margin

(Rs Mn)

22.1%

16.7%

340

295

Q1FY24

Q1FY25

EBITDA

EBITDA Margin

PAT

(Rs Mn)

14.5%

8.3%

222

147

Q1FY24

Q1FY25

PAT

PAT Margin

Note: PAT, PAT Margin and EPS are adjusted for Exceptional Items.

Q1FY25 Financial Performance – P&L Statement

(INR Mn)	Q1FY25	Q1FY24	Y-o-Y	Q4FY24	Q-o-Q
Revenue From Operation	1,767	1,537	14.9%	2,250	-21.5%
COGS	1,023	801		1,350	
Gross Profit	743	736	0.9%	900	-17.4%
<i>Gross Margin</i>	42.1%	47.9%		40.0%	
Employee Expense	191	141		170	
Other Expense	258	255		297	
Total Expense	448	396		468	
EBITDA	295	340	-13.2%	432	-31.6%
<i>EBITDA Margin</i>	16.7%	22.1%		19.2%	
Depreciation	62	37		49	
Finance Cost	44	5		21	
Other Income	10	12		13	
Exceptional Item				-3	
PBT	200	309	-35.5%	372	-46.4%
TAX	51	87		115	
PAT	147	222	-33.9%	257	-42.8%
<i>PAT Margin</i>	8.3%	14.5%		11.4%	

Financial Performance over the years – Key Metrics

Revenue from Operations- Growth Trends

(Rs Mn)


FY20 FY21 FY22 FY23 FY24

FY20-24 CAGR:

25%

112%


32%



Revenue – by Business Verticals


(Rs Mn)

Pharma Intermediates Specialty Chemicals




Revenue from exports

(Rs Mn)




Share of Top Customers - FY24




Financial Performance over the years – Key Metrics (cont'd)


EBITDA and EBITDA Margins (%)




PAT and PAT Margins (%)



Long term Borrowings and Gross Block



Returns Profile



Note: PAT, PAT Margin, EPS, ROE and ROCE are adjusted for Exceptional Items.

Note: Suppressed ROE and ROCE due to ongoing capital expenditure.

Financial Performance over the years - Profit and Loss

Particulars (INR mn)	FY21	FY22	FY23	FY24
Revenue from Operations	3,406	5,201	6,167	7,175
Other Income	14	28	43	75
Total Income	3,420	5,229	6,210	7,250
Cost of materials consumed	1,749	2,823	3,459	4,402
Changes in inventories of finished goods, traded goods and work-in-progress	48	(95)	(150)	(285)
Employee benefits expenses	210	414	488	631
Finance cost	56	64	24	59
Depreciation and amortisation expenses	42	101	123	161
Other expenses	598	1,008	1,144	1,142
Profit before tax and exceptional items	717	914	1,122	1,140
Exceptional profit / (loss)	-	-	-	(321)
Tax expense	177	195	289	332
Profit for the year	540	719	833	487

Note: Exceptional item includes full impairment of investment in JV - Ami Oncotheranostics LLC


Financial Performance over the years - Balance Sheet

<i>Assets (INR mn)</i>	FY21	FY22	FY23	FY24
Property, plant and equipment	1,422	1,584	1,844	3,229
Right of use assets	184	194	374	372
Capital work-in-progress	2	30	255	1,254
Goodwill	-	-	203	568
Other intangible assets	257	267	211	103
Investments	14	17	17	2
Other financial assets	27	108	65	26
Other non-current assets	64	97	129	447
Total non-current assets	1,970	2,297	3,098	6,001
Inventories	604	1,122	1,192	1,567
Trade receivables	1,207	1,637	2,303	2,064
Cash and cash equivalents	27	103	305	297
Other bank balances	-	893	281	236
Loans	3	6	13	16
Current tax assets (net)	-	49	32	25
Other current assets	321	481	445	753
Total current assets	2,162	4,291	4,571	4,958
Total assets	4,133	6,589	7,669	10,959

<i>Equity and Liabilities (INR mn)</i>	FY21	FY22	FY23	FY24
Shareholder's equity	1,669	5,223	5,939	6,828
Borrowings	726	6	6	1,136
Provisions	44	4	7	13
Deferred tax liabilities (net)	33	63	88	130
Total non-current liabilities	803	73	101	1,280
Borrowings	640	3	30	1,030
Trade payables	848	1,184	1,420	1,346
Other current liabilities	151	46	64	344
Provisions	10	60	114	132
Current tax liabilities (net)	11	-	-	-
Total current liabilities	1,660	1,293	1,628	2,852
Total liabilities	2,463	1,366	1,730	4,131
Total equity and liabilities	4,133	6,589	7,669	10,959

Shareholder Information

Shareholding as on 30th June 2024



Source: BSE

Share Information as on 30th June 2024

NSE Ticker	AMIORG
BSE Ticker	543349
Market Cap (Rs. Cr)	5,287
Shares Outstanding	4,09,05,561
3M ADTV (Shares)*	2,46,319
3M ADTV (Rs. cr)*	31.09
Industry	Specialty Chemicals

*Source: NSE

2. Company Overview

- Company Overview
- Our Journey
- Our Products
- Strong and Long-term relations with Diversified Customers across Geographies
- Our Manufacturing Facilities
- Superior R&D Capabilities
- Our Founders
- Our Leadership
- What makes us different



Ami Organics – At a Glance

- One of the leading Research and Development driven manufacturer of Specialty Chemicals
- Focused on the development and manufacturing of:
 - Advanced Pharmaceutical Intermediates
 - Specialty Chemicals
- Serves diverse end-use industries including Pharmaceuticals, Cosmetics, Fine Chemicals, Semiconductor, Battery Chemicals, among others

7,250

FY24 Total Revenue
(INR mn)

1,285

FY24 EBITDA
(INR mn)

808

FY24 Adj. PAT
(INR mn)

500+

Customers

~45

Countries
(Customer locations)

56%

Export%
(FY24)

4

Manufacturing
Facilities
(Gujarat, Uttar Pradesh)


1

R&D Facility
State of art in-house R&D facility
recognized by DSIR in Gujarat

Business Segments




**Advanced Pharmaceutical
Intermediates**




**Specialty
Chemicals**

Revenue Mix (FY24)



**Advanced Pharmaceutical
Intermediates**




**Specialty
Chemicals**

570+ Products

Invoiced to customers in last 5 years


The Evolution





Advanced Pharmaceutical Intermediates

- ~**550 Products** invoiced in last 5 years
- Intermediates across **17+ therapeutic areas**
- ~**95% Chronic Therapy** focus
- Majorly backward integrated to **Basic Chemical** level
- **Market leader for key intermediates across the globe**



Specialty Chemicals

- **Parabens & Paraben formulations**
- **Methyl Salicylate**
- Niche **KSMs** for cosmetics, finechem and agrochem companies
- **Semiconductor Chemicals** business through **Baba Fine Chemicals - Only Indian player in Photo Resist Chemicals**
- **Electrolyte additives** used in manufacturing cells for energy storage devices - **First Company in India to manufacture electrolyte additives**

Strong and Long-term Relations with Diversified Customers across Geographies

500+

Customers

~45


Countries
(customer locations)

30+


Customers associated
since last 10 years

- Well established long-term relations with domestic customers as well as MNCs across large and fast-growing markets
- Diversified customer base
- Long term supply contract with key customers
- Prolonged adherence to stringent client requirements leading to new business from existing customers as well as from new clients


Revenue Contribution from Top Customers - FY24




Global Customer Base Spread across...



Export Revenue



Key Export Destinations (FY24)



Strong and Long-term relations with Diversified Customers across Geographies (cont'd)

Advanced Pharma Intermediates (Top Clients)

Generic



Innovators



Specialty Chemicals (Top Clients)

State-of-the-Art Manufacturing Facilities

76,891
Total Land Area (sq mtrs)

~1,100
Total Installed Capacity (KL)

Sachin, Gujarat



Land Area (sq mtrs) **Installed Capacity (KL)**

8,250 **144**

- Multipurpose facility equipped for production of advanced pharmaceutical intermediates
- One block with 13 separate product lines, 40 reactors, 17 dryers, zero-liquid discharge based ETP and SBT system

Ankleshwar, Gujarat



Land Area (sq mtrs) **Installed Capacity (KL)**

10,375 **442**

- Inaugurated in Dec 2023, for production of advanced pharmaceutical intermediates
- Three blocks with 80+ reactors, ~35 dryers, ETP system
- Automated plant with Fully operational DCS (Distributed Control System) and PTS (Powder Transfer System)

Jhagadia, Gujarat



Land Area (sq mtrs) **Installed Capacity (KL)**

56,998 **512**

- Multipurpose facility for production of parabens, methyl salicylate and other specialty chemicals
- Consists of 26 stainless steel and glass reactors with fully dedicated lines for paraben and methyl salicylate production
- Equipped with state of art ETP treatment facility
- Unused 15,830 sq mtrs land available to explore brownfield expansion opportunities

Greater Noida, UP



Land Area (sq mtrs) **Installed Capacity (KL)**

999 **1.8**

- Manufacturing of electronic grade photo resist chemicals
- 7 lab room with glass line capacity of 500 litres and 14 glass assembly with capacity of 1,300 litres



Note: ETP - Effluent Treatment Plan; SBT - Soil Bio Technology

R&D Centric Organization...

1 R&D Lab

23,681 sq. ft.

State of art R&D facility at Sachin supported by an ADL

2 Technology

ADL fully supported by analytical instruments like:

- LCMASS
- GCMASS
- UV spectrophotometer
- Photo stability & stability chambers, etc.

3 State-of-the-Art Equipment

- Modern fume hood system
- Autoclave
- High vacuum distillation assembly
- Glass reactor assembly, etc.

4 R&D Strategy

R&D team focused on:

- NCE product
- New product development
- Process improvement

5 Team

Specialized team of 110+ members including:

- 11 Ph.Ds
- 18 Engineers

6 Patents

15 process patents filed for advanced pharma intermediates:


- 10 patents granted
- 1 patent published
- 4 in process of examination

R&D Expenditure

(INR mn)


65	70	77	141
----	----	----	-----

R&D expenditure as % of Revenue from Operations



Superior R&D Capabilities (Cont'd)

Our Capabilities in Key Chemistry




**AMI Organics R&D
Centre in Surat**



Continuous Flow Reactor

- Continuous flow reactors are **more efficient, and sustainable** when compared to manufacturing products using traditional reactors.
- AMI has successfully developed capabilities in **Plug Flow, Catalytic fixed-bed flow, Tubular flow** kind of reactors
- This technology **reduces the cycle time to manufacture** a product which leads to **lower utilization of utilities**
- The space required to fit a flow reactor is considerably lower than the traditional reactors.
- AMI Organics has successfully developed and **commercialized Chlorination, Nitration, Etherification, Ammoxidation, Diazotization and Oxidation in flow reactor**
- AMI Organics successfully **commissioned Photo Chlorination and Grignard in pilot flow reactor**



Our Founders



Nareshkumar Patel

Executive Chairman, MD

- Mr. Nareshkumar Patel is founder of the Company
- He has been associated with the Company since its inception and has extensive experience in the global generic pharma business
- He is responsible for handling the Chemical Engineering and Product Implementation divisions of the Company
- He holds a Bachelor degree in Engineering from Gujarat University

- Mr. Chetankumar Vaghasia is one of the co-founders of the Company
- He has been associated with the Company since its inception and has deep experience in the chemical industry
- He is responsible for handling the Procurement and Administration divisions of the Company
- He holds a Diploma in Man-made Textile Processing from Surat, Gujarat



Chetankumar Vaghasia

Whole – time Director

Our Leadership

Board of Directors



Virendra Mishra

Whole – time Director

- Holds Master of Science degree
- Previously associated with K.A. Malle Pharmaceuticals and Surya Organics & Chemicals



Girikrishna Maniar

Non – executive, Independent Director

- Holds a Bachelor of Science degree and is a fellow member of the Institute of Cost Accountants of India



Richa Goyal

Non – executive, Independent Director

- Holds Bachelor of Commerce degree and an LLB degree; Fellow member of the Institute of Company Secretaries of India
- Currently associated with “Richa Goyal and Associates”



Hetal Gandhi

Non – executive Independent Director

- 34+ years of experience in the financial services industry
- Holds Bachelor of Commerce degree and is an Associate Member of the ICAI
- Co-founder and MD of Tano India Advisors



Dr. Anita Bandyopadhyay

Independent Director

- Acclaimed HR consultant with extensive expertise in Leadership Development and Talent Management
- Holds a Doctorate in Applied Psychology from Kolkata University
- She has experience in Pharma, FMCG, Retail, and B2B business sectors



Mr. Ram Mohan Lokhande

Whole – time Director

- Holds B.E. Chemicals from NIIT, Warangal
- 20+ years of vast experience with leading pharmaceutical and chemical companies
- Previously associated with Glenmark Pharmaceuticals, Dr. Reddy Laboratories and Macleod’s Pharmaceuticals

Senior Management Personnel

Bhavin Shah

Chief Financial Office

- Holds Bachelor of Commerce degree and is a qualified Chartered Accountant from ICAI
- Previously associated with Sun Pharma Group and Deloitte Haskins & Sells

Ajit Kumar Choubey

President – Technical

- Holds Doctor of Philosophy degree in Chemistry
- Previously associated with IPCA Laboratories

Hemant Patel

SGM – Human Resource

- Holds Master of Labour Management and Post Graduate Diploma in Personnel Management and Industrial Relations

Sanjay Vasoya

AVP – R&D

- Holds Ph.D. and M.Sc in Organic Chemistry
- Previously associated with Teva Pharmaceuticals, Alembic and Rubamin Pharma

Gaurav Bhandari

Senior Manager – Marketing

- Holds Bachelor of Technology (Bioinformatics) and PGDM degree
- Previously associated with Go Zoop Online Pvt Ltd and Social PR Outsourcing Pvt Ltd

What Makes Us Different ?



Niche Product Portfolio with a Strong Market Share

- Niche products with limited competition focused on the chronic disease market
- Market leader for the key intermediates across the globe



High Entry Barriers

- A long gestation period to be enlisted as a supplier
- The involvement of complex chemistries
- Regulatory requirements creating hurdles for new entrants



Diversified Products to Support Future Growth

- A long tail of 570+ products which includes products that are in development or testing phase, some of which have the potential to support our growth in coming years



Diversified Customer Base across Geographies

- Successful track record of working with innovators with sticky customers across products
- Trusted and reliable supplier of intermediates globally
- "Preferred Supplier" status for key molecules



Reputation for Innovative Product Launches Supported by Robust R&D

- First to Market in most of the products
- For a single intermediate, capability to provide product from N-1 to N-12 stage with different routes of synthesis




Robust Cost Management / Process Improvements

- ~71% of raw material outsourced from domestic vendors
- Continuous focus on process optimization and improvement has led to cost leadership in the industry with high quality products
- Focus on newer technologies to manufacture products e.g. – continuous flow processes

3. Advanced Pharma Intermediate

- A leading Advanced Intermediate Manufacturer from India
- Our Business Model
- Uniqueness of our business model
- Our Strategy and Outlook
- Industry Overview



Advanced Pharmaceutical Intermediates



5,678
FY24
Revenue
(INR mn)



17+
Therapeutic
Areas



150+
Customers
in FY24



25+
Countries
(Customer locations)




15
Process Patents
(1 patent published; 10
patents granted and 4 patents
applied)




2
Manufacturing
Facilities
Surat and Ankleshwar, Gujarat
(Ankleshwar plant is under
development)

Historical Business Performance


(INR mn)



Segment Revenue



Our Business Model – Advanced Intermediates for Pharmaceuticals



CDMO

- Contract Manufacturing for big pharma companies
- Exclusive long term supply contracts



Regulatory market business


- Supplying NCE molecules to the pharma innovator companies
- Supplying intermediates to the innovator pharma companies for the products under patent
- Supplying intermediates to the innovator pharma companies for the off-patent products



Emerging market business

- Supplying intermediates to the generic API manufacturer
- First mover advantage
- Sustaining market through Cost efficiency

Uniqueness of our business model



Chronic Therapy focused

- ~95% of the products catered on fast-growing Chronic segment

Wide Product Basket

- Wider basket of products, with 550+ molecules

R&D Leadership

- First to market with target products
- Products available with different routes of synthesis
- Capabilities to furnish products from n-1 to n-12 stages

Presence across value chain

- AMI is present across the value chain of the intermediates business, from supplying NCE to innovators, providing a wide range of products with the different routes of synthesis and different levels of intermediates


Preferred Supplier

- Our unique business model positions us perfectly to be the preferred suppliers for the innovators as well as big generic pharma companies

Strong Customer Base

- As one of the biggest manufacturers of intermediates for the target therapies, AMI is in a unique position to cross-sale new molecules to existing clients.
- AMI has more than 1 product with all major customers


Our Strategy – Advanced Pharmaceutical Intermediates



Industry Overview (1/2)


Global API Market

(USD bn)






Global Pharmaceutical Intermediates Market

(USD bn)



Global API Market Split by Therapy



	CAGR (2018-23)	CAGR (2023-28E)
Oncology	11%	13%
Cardiovascular	4%	5%
CNS	6%	5%
Anti-Infective	4%	5%
Immunology	8%	9%
Endocrinology	8%	7%
Anti-Coagulant	8%	8%
Gastrointestinal	4%	5%
Anti-Depressant	4%	3%
Parkinson's Disease	7%	8%

■ Oncology ■ Cardiovascular ■ CNS ■ Anti-Infective ■ Immunology ■ Endocrinology ■ Anti-Coagulant ■ Gastrointestinal ■ Anti-Depressant ■ Parkinson's Disease ■ Others

4. Specialty Chemicals

- Speciality Chemicals - Overview
- Our Strategy and Outlook
- Industry Overview



Speciality Chemicals



1,497
FY24
Revenue
(INR mn)



3
Business
Segments

- Specialty Chemicals for various industries e.g. Cosmetics, Finechem, Agrochem, etc.
- Battery Chemicals
- Semiconductor Chemicals



40+
Products



340+
Customers



40+
Countries
(Customer locations)




2
Manufacturing
Facilities


Jhagadia, Gujarat and Greater Noida, Uttar Pradesh

Historical Business Performance

(INR mn)




Segment Revenue



Our Strategy – Speciality Chemicals

Development and entry into newer applications
having strong entry barriers



Continue to work on **improving operational efficiencies** to deliver better margins



Leverage the technology and capability of Baba Fine Chemicals to **expand the semiconductor chemical business**




Grow the Battery Chemicals segment –
Electrolyte additives sample approved at plant scale from 6 customers

Industry Overview (2/2)


Global Specialty Chemicals Market

(USD bn)




Global Electrolyte Additives and Electrolyte Solutions Market

(USD bn)



Global Photoresist Chemicals and Semiconductor Chemicals Market

(USD bn)



5. Working towards better tomorrow



ESG Focus – Working towards a Better Tomorrow



Environment

- Zero Liquid Discharge based in-house effluent plant at Sachin facility
- 80% of wastewater recycled
- Developing greenbelt in Sachin
- All the manufacturing units are ISO 9001:2015, ISO 14001:2015 certified
- Awarded Gold Rating accreditation from EcoVadis, recognizing the company's outstanding commitment to sustainability



Social

- Company's Sachin facility is SA 8000:2014 certified
- The SA8000® standard is the leading social certification standard for factories and organizations across the globe
- Occupational health and safety management system at Sachin facility has been certified to be in compliance with ISO 45001:2018 standards by the Bureau Veritas Certification Holding SAS – UK Branch



Governance

- 50% of the board constitutes of independent directors
- Audit and Nomination and Remuneration Committee are headed by independent directors

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from AMI Organics Ltd.

Contact Us

For more information please contact:



Ami Organics Limited

Ekta Srivastava

Company Secretary & Compliance Officer

cs@amiorganics.com

Rahul Thakur

Senior Manager – Investor Relations

Rahul.thakur@amiorganics.com

